N-Acetylcysteine Protection Against Radiation Induced Cellular Damage

PHASE2CompletedINTERVENTIONAL

Enrollment

181

Participants

Timeline

Start Date

September 2, 2020

Primary Completion Date

December 2, 2024

Study Completion Date

December 2, 2024

Conditions

Cardiac Arrhythmia

Interventions

DRUG

Acetyl cysteine

1200 mg of NAC are intravenously administrated 1 hour prior to carrying out CAP.

Trial Locations (1)

Centro Cardiologico Monzino, Milan

All Listed Sponsors

collaborator

Ministry of Health, Italy

OTHER_GOV

lead

Centro Cardiologico Monzino

OTHER

NCT04154982 - N-Acetylcysteine Protection Against Radiation Induced Cellular Damage | Biotech Hunter | Biotech Hunter